CD47 and neoplasm: RRx-001, inhibiting CD47 transcription, exhibits no obvious hematologic or systemic toxicity in clinic, suggesting that downregulating tumor CD47 expression by using small-molecule inhibitors may avoid hematological side effects48,49.